Calithera Biosciences, Inc.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company…
Biotechnology
US, South San Francisco [HQ]
CALA/Financial Reporting
Income Statements
11 Sheets · Starting from 2012In Million USD. Margins, Growth Rates In %
| Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | 25.00 | 22.00 | - - | - - | 9.00 | - - | |
|
EPS
|
-20.21 | -31.36 | -93.34 | -36.18 | -39.01 | -16.89 | -28.12 | -36.50 | -25.73 | -44.77 | -7.94 | |
| Diluted in mil. | -20.21 | -31.36 | -93.34 | -36.18 | -39.01 | -16.89 | -28.12 | -36.50 | -25.73 | -44.77 | -7.94 | |
|
Profit
|
- - | - - | - - | - - | - - | 25.00 | 22.00 | -1.00 | -1.00 | 8.00 | -1.00 | |
| Gross Margin | - - | - - | - - | - - | - - | 100.00 | 100.00 | - - | - - | 85.29 | - - | |
| Pre Tax | -7.00 | -12.00 | -21.00 | -32.00 | -38.00 | -27.00 | -54.00 | -89.00 | -90.00 | -115.00 | -39.00 | |
| Profit Margin | - - | - - | - - | - - | - - | -107.21 | -245.48 | - - | - - | -1,180.39 | - - | |
| ETR | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Net | -7.00 | -12.00 | -21.00 | -32.00 | -38.00 | -27.00 | -51.00 | -86.00 | -88.00 | -165.00 | -18.00 | |
| Profit Margin | - - | - - | - - | - - | - - | -107.21 | -231.29 | - - | - - | -1,695.77 | - - | |
| EBITDA | -4.00 | -12.00 | -21.00 | -32.00 | -37.00 | -29.00 | -57.00 | -88.00 | -88.00 | -115.00 | -38.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | -114.37 | -257.40 | - - | - - | -140.34 | - - | |
| Operating Income | -7.00 | -12.00 | -21.00 | -32.00 | -38.00 | -29.00 | -57.00 | -92.00 | -91.00 | -115.00 | -42.00 | |
| Operating Margin | - - | - - | - - | - - | - - | -114.37 | -257.40 | - - | - - | -1,183.93 | - - | |
| Interest Income | - - | - - | - - | - - | - - | 1.00 | 2.00 | 3.00 | 1.00 | - - | - - | |
| Loss | -7.00 | -12.00 | -21.00 | -32.00 | -38.00 | -55.00 | -79.00 | -92.00 | -91.00 | -74.00 | -42.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | -1.00 | -1.00 | -1.00 | -1.00 | |
|
Operating Expenses
|
-7.00 | -12.00 | -21.00 | -32.00 | -38.00 | -55.00 | -79.00 | -92.00 | -91.00 | -74.00 | -40.00 | |
| R&D | -6.00 | -9.00 | -16.00 | -23.00 | -27.00 | -43.00 | -66.00 | -76.00 | -71.00 | -53.00 | -28.00 | |
| G&A | -1.00 | -2.00 | -5.00 | -9.00 | -10.00 | -12.00 | -13.00 | -16.00 | -20.00 | -20.00 | -13.00 | |
| SG&A | -1.00 | -2.00 | -5.00 | -9.00 | -10.00 | -12.00 | -13.00 | -16.00 | -20.00 | -20.00 | -12.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Expenses | - - | - - | - - | - - | - - | -1.00 | -2.00 | -3.00 | -1.00 | - - | -2.00 | |
|
WA Shares Outstanding
|
- - | - - | - - | - - | - - | 1.00 | 1.00 | 2.00 | 3.00 | 3.00 | 4.00 | |
| Diluted | - - | - - | - - | - - | - - | 1.00 | 1.00 | 2.00 | 3.00 | 3.00 | 4.00 |